REG - AOTI, Inc. - 2025 Annual Report and Notice of AGM

AotiAnnouncement

21/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260421:nRSU1649Ba&default-theme=true

RNS Number : 1649B  AOTI, Inc.  21 April 2026

21 April 2026

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

2025 Annual Report and Notice of Annual General Meeting

 

AOTI, INC. (AIM: AOTI), a medical technology group focused on delivering
outcomes-based care at home, by more durable healing of wounds and the
prevention of amputations, announces that electronic copies of the Company's
Annual Report and Financial Statements for the year ended 31 December 2025,
together with the 2026 Notice of Annual General Meeting (the 'Notice'), Form
of Instruction and Proxy forms will shortly be available on the Company's
website at:

https://aotinc.net/investors/financial-reports-publications-2/
(https://aotinc.net/investors/financial-reports-publications-2/)

The Annual General Meeting ('AGM') will be held at 10:00am British Summer Time
(BST) on Thursday, 21 May 2026 at the offices of Burges Salmon LLP, 6 Great
New Street, London, EC4A 3BN, United Kingdom.

Shareholders are encouraged to vote on the resolutions to be put to the AGM by
proxy whether or not they intend to attend. Voting by proxy prior to the AGM
does not affect shareholders' right to attend the AGM and vote in person
should they so wish. Holders of Depositary Interests will be sent a Form of
Instruction for voting their shares and all other shareholders will be sent
the Notice and Form of Proxy; with all items posted on or around 22 April
2026.

Full details of the operation and arrangements for the AGM are set out in the
Notice.

 

ENDS

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer         +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer           ir@aotinc.net (mailto:ir@aotinc.net)

 Peel Hunt LLP (Nominated Adviser and Joint Broker)

 Dr. Christopher Golden, James Steel                 +44 (0)20 7418 8900

 Panmure Liberum Limited (Joint Broker)              +44 (0)20 3100 2000

 Emma Earl, Will Goode, Mark Rogers

 Rupert Dearden

 FTI Consulting (Financial PR & IR)                  +44 (0)20 3727 1000

 Ben Atwell, Simon Conway,                           AOTI@fitconsulting.com (mailto:AOTI@fitconsulting.com)

 Natalie Garland-Collins

 

 

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomized controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalizations and 71 per cent. reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA), Europe
(CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. TWO(2)(®) therapy has
also recently received positive coverage recommendations from the Federal
Joint Committee (G-BA) in Germany and National Institute for Health and Care
Excellence (NICE) in the United Kingdom. Also see www.aotinc.net
(http://www.aotinc.net)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABBGDSUXDDGLG



            Copyright 2019 Regulatory News Service, all rights reserved